Atezolizumab-MMAE

Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. Atezolizumab-MMAE is composed of a humanized anti-PD-L1 antibody (Atezolizumab) (HY-P9904), a lysosomally cleavable dipeptide linker (valine-citrulline), a tubulin inhibitor (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575) . Atezolizumab-MMAE has a potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effect. Atezolizumab-MMAE has a significantly anti-tumor activity in MC38 xenograft PD-1-humanized immune system mice model[1][2].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis; Microtubule/Tubulin

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Purity

98.04

Smiles

[Atezolizumab-MMAE]

References & Citations

[1]Xiao D, et al. Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021 Nov; 116:105366.|[2]Zanello A, et al. Anti-PD-L1 immunoconjugates for cancer therapy: Are available antibodies good carriers for toxic payload delivering? Front Pharmacol. 2022 Aug 16; 13:972046.